Rationally Engineered D-Amino Acid Peptide DT7-3 Combats Multidrug-Resistant Helicobacter pylori via a Novel...

Area of Science:

• Microbiology
• Peptide Therapeutics
• Antimicrobial Resistance

Background:

• Helicobacter pylori (H. pylori) is a major cause of gastritis, ulcers, and gastric cancer.
• Increasing multidrug-resistant (MDR) H. pylori strains, especially to clarithromycin, metronidazole, and levofloxacin, limit treatment options.
• Novel antimicrobial agents with distinct mechanisms are crucial to overcome resistance and reduce gastric cancer risk.

Purpose of the Study:

• To design and synthesize a novel antimicrobial peptide, DT7-3, an all-D-amino acid enantiomer.
• To evaluate the efficacy and mechanism of action of DT7-3 against MDR H. pylori strains.
• To assess the safety and selectivity profile of DT7-3.

Main Methods:

• Broth microdilution method to determine minimum inhibitory concentrations (MICs) against standard and clinical MDR H. pylori isolates.
• Scanning electron microscopy (SEM) for morphological analysis.
• Fluorescence-based assays for anti-adhesion activity.
• Real-time qPCR to quantify virulence gene expression (babA, ureA, vacA).
• Biocompatibility assays using erythrocytes, gastric epithelial cells (GES-1), and gut microbiota.

Main Results:

• DT7-3 demonstrated potent activity (MIC 1-32 µg/mL) against all tested H. pylori strains, including MDR isolates (54.5% MDR in clinical samples).
• A 'triple-hit' mechanism was identified: rapid membrane disruption, significant inhibition of bacterial adhesion (~60%), and downregulation of virulence factors (babA, ureA, vacA).
• DT7-3 exhibited an excellent safety profile with negligible hemolysis (<5%) and low cytotoxicity to GES-1 cells (Selectivity Index > 32), and high selectivity over beneficial gut microbiota (Selectivity Index > 16).

Conclusions:

• The engineered D-peptide DT7-3 is a potent candidate for combating MDR H. pylori.
• Its multifaceted mechanism targeting bacterial viability and virulence factors makes it a promising lead compound for next-generation eradication therapies.
• DT7-3 offers a potential strategy to reduce the global burden of H. pylori-associated diseases.